2 Information about darolutamide

Marketing authorisation indication

2.1 Darolutamide (Nubeqa, Bayer) is indicated for 'the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for darolutamide.


2.3 The list price of darolutamide is £4,040.00 for a 28‑day supply of 112 tablets, each containing 300 mg (excluding VAT, BNF online accessed March 2023).

2.4 The company has a commercial arrangement. This makes darolutamide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)